Formulated and filled in Phoenix from compounds we already carry on their own. Each vial's composition is published to the milligram, and one CoA covers every component in the lot.
01Open formulasMilligrams of each component per vial, printed on the label and this page. No proprietary-blend math.
02Single compounds, side by sideEvery component is also sold on its own, so you can run the blend against its parts.
03One lot, one CoA, every componentThe QR code on each vial opens a CoA with identity and content results for each peptide in the blend.
The formulation sheets
10 vials per pack · lyophilized · US-made
Each sheet’s Research rationale summarizes published research on the individual components and why we pair them. It describes the research literature, not what a blend does: no Signature blend has been studied as a combination. For laboratory research use only.
The BPC-157 / TB-500 base with the tripeptide bioregulator Cartalax added.
Research rationaleWhat the science says
Why these together
BPC-157 and thymosin β4 (TB-500) are the two peptides most often studied in tissue-repair models, and the literature studies them through different mechanisms. BPC-157 work centers on angiogenesis and growth-factor signaling; thymosin β4 is an actin-sequestering protein studied in cell migration. R3 adds Cartalax, a short bioregulator studied in cell-renewal culture models, so one lot covers all three lines of inquiry.
What's been studied
BPC-15715-amino-acid fragment of a gastric protein. Studied in rodent tendon, ligament and muscle injury models.
TB-500Thymosin β4, a 43-amino-acid actin-binding protein. Studied in wound and cardiac repair models.
CartalaxAla-Glu-Asp tripeptide. Studied in organotypic and fibroblast culture models.
The ratio
Equal mass of BPC-157 and TB-500, the pairing used most widely in research supply. Cartalax is added at half mass, which is still the largest molar share because of its low molecular weight.
EvidencePreclinical: animal and cell-culture studies. No published studies of the three together.
Three bioregulators from our catalog, co-lyophilized in equal parts.
Research rationaleWhat the science says
Why these together
All three come out of the same research program: Vladimir Khavinson’s group’s work on peptides of the pineal gland and thymus. Epithalon and Pinealon are short synthetic sequences; Thymalin is a thymic peptide fraction. They are studied in aging research, often side by side, which makes an equal-parts trio a convenient single lot.
What's been studied
EpithalonAla-Glu-Asp-Gly tetrapeptide. Studied for telomerase activity in human somatic cell culture.
PinealonGlu-Asp-Arg tripeptide. Studied in neuronal cell and rat models of oxidative stress.
ThymalinThymic polypeptide fraction. Studied for immune parameters, largely in Russian-language literature.
The ratio
Equal mass of each component, 10 mg apiece.
EvidencePreclinical, mostly from one research group, with limited independent replication.
The copper tripeptide GHK-Cu with the octapeptide SNAP-8.
Research rationaleWhat the science says
Why these together
GHK-Cu and SNAP-8 are reference peptides in skin and cosmetic-ingredient research, and they act on unrelated targets. GHK-Cu is a copper-binding tripeptide studied for extracellular-matrix and gene-expression effects in fibroblasts. SNAP-8 is a synthetic octapeptide designed to compete with SNAP-25 in SNARE complex assembly. Pairing them puts both pathways in one lot.
What's been studied
GHK-CuCopper(II) complex of Gly-His-Lys. Studied in fibroblast, collagen and gene-expression research.
SNAP-8Acetyl octapeptide-3, an elongated analog of acetyl hexapeptide-3 (Argireline). Studied in vitro for SNARE complex interference.
The ratio
5 : 1 by mass, reflecting GHK-Cu’s much higher typical concentration in formulation research.
EvidenceIn vitro and cosmetic-formulation studies. No published studies of the pair.
Both peptides are studied in immune and inflammation research, through different routes. Thymosin α1 is a 28-amino-acid thymic peptide studied mainly for T-cell maturation and signaling. KPV, the C-terminal tripeptide of α-MSH, is studied for inflammatory signaling in intestinal epithelial cells, where it is taken up by the PepT1 transporter.
What's been studied
Thymosin Alpha-128-amino-acid thymic peptide with a long clinical research history outside the US.
KPVLys-Pro-Val, the C-terminal tripeptide of α-MSH. Studied in cell and mouse models of intestinal inflammation.
The ratio
KPV at twice the mass of Thymosin α1. Because KPV is so small, that’s roughly 18 molecules of KPV for every one of Thymosin α1.
EvidenceThymosin α1: extensive literature, including clinical research outside the US. KPV: preclinical. No published studies of the pair.
The mitochondrial-derived peptide MOTS-c with the tetrapeptide SS-31.
Research rationaleWhat the science says
Why these together
Both peptides are studied in mitochondrial research, from opposite directions. MOTS-c is encoded in mitochondrial DNA and studied as a signal from the mitochondrion to the rest of the cell, including AMPK activation. SS-31 is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane and is studied for its effect on the membrane itself.
What's been studied
MOTS-c16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. Studied in mouse metabolic models.
SS-31Elamipretide, a cardiolipin-binding tetrapeptide that has been through human clinical trials.
The ratio
Equal mass. SS-31’s lower molecular weight gives it about 3.4 times the molar share.
EvidenceMOTS-c: preclinical. SS-31: preclinical and clinical-trial literature. No published studies of the pair.
Wholesale accounts can commission a private blend from any compounds in our catalog — your ratios, filled in Phoenix, documented with the same per-component CoA. Add your own label with white label.
